Abstract 459P
Background
With cancer as the leading cause of death in Korea and globally, addressing non-cancer mortality, specifically cardiovascular disease, is critical. Dyslipidemia, a significant risk factor for cardiovascular disease, requires proper management in cancer survivors. This study aims to analyze factors associated with undertreatment of dyslipidemia in cancer survivors and investigate the impact of the National Health Screening Program (NHSP) on undertreatment in Korea.
Methods
This cross-sectional study analyzed data from the Korea National Health and Nutrition Survey (KNHANES) conducted between 2007 and 2019. It included 2,226 participants (792 males, 1,434 females) aged 40-75 who had a history of cancer. Self-reported questionnaires collected information following the 2018 Cholesterol Treatment Guidelines by the American College of Cardiology/American Heart Association. Multiple logistic regression analysis with integrated weights was performed.
Results
Among cancer survivors, 16.3% received treatment for dyslipidemia. Of those who were untreated, 46.64% had normal blood lipid levels, while 37.0% were not receiving adequate treatment. Additionally, 72.7% of cancer survivors participated in the NHSP, and the undertreatment rate for dyslipidemia was significantly lower in the screened group compared to the non-screened group (34.14% vs. 44.78%; P < 0.001). Adjusting for age and sex, cancer survivors in the non-screened group had a significantly higher risk of not receiving appropriate dyslipidemia treatment (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.10, 1.97). Even after considering socioeconomic and cancer-related factors, the non-screened group remained significantly associated with undertreatment of dyslipidemia (OR 1.36, 95% CI: 1.02, 1.82), especially among female cancer survivors (OR 1.49, 95% CI: 1.05, 2.14).
Conclusions
This study is the first to assess the association between NHSP and undertreatment of dyslipidemia. Encouraging cancer survivors to participate in the NHSP would be an effective strategy to reduce the incidence and mortality of concurrent cardiovascular disease, ultimately improving the overall health of cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract